XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing We apologize, but this video has failed to load. Try refreshing ...
(MENAFN- GlobeNewsWire - Nasdaq) XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing With the clinical ...
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX ...
XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...
The new drug development program - XRx-026 - will focus on the treatment of individuals who have gout and are intolerant to allopurinol. With the clinical development of XORLO TM 1 having advanced ...
XORTX Therapeutics Inc ( ($TSE:XRTX) ) has issued an update. XORTX Therapeutics Inc. announced a change of auditor, appointing Davidson & Company ...
Diagnosis Tophaceous gout associated with urate nephropathy in a patient intolerant to allopurinol. Management Acute polyarthritis was successfully managed by intravenous bolus methylprednisolone ...